9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors
To evaluate the safety, tolerability, and preliminary efficacy of 9MW2821 in combination with other anti-tumor agents in patients with advanced gynecological malignancies.
Gynecological Malignancies
DRUG: 9MW2821+other anticancer therapy
ORR, Objective Response Rate, Up to 24 months
DoR, Duration of Response, Up to 24 months|TTR, Time to Response, Up to 24 months|DCR, Disease Control Rate, Up to 24 months|PFS, Progression Free Survival, Up to 24 months|OS, Overall Survival, Up to 24 months|Pharmacokinetic parameter：total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE), Maximum observed concentration (Cmax), 24 months|Pharmacokinetic parameter：total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE), Area under the concentration-time curve (AUC), 24 months|Pharmacokinetic parameter：total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE), Half-life (t1/2), 24 months|Pharmacokinetic parameter：total antibody (TAb), antibody drug conjugate (ADC), and Monomethyl Auristatin E (MMAE), Clearance (CL), 24 months|Incidence of Anti-Drug Antibody (ADA), ADA, 24 months
To evaluate the safety, tolerability, and preliminary efficacy of 9MW2821 in combination with other anti-tumor agents in patients with advanced gynecological malignancies.